New hope for High-Risk breast cancer: drug added to radiation in groundbreaking trial
NCT ID NCT05996107
Summary
This study is testing whether adding a drug called ribociclib to standard radiation therapy is safe for women with high-risk, hormone-positive breast cancer. The goal is to see if this combination can better control the cancer and prevent it from coming back after surgery. Researchers will enroll about 30 participants to find the right dose and monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UHCMC Seidman Cancer Center
RECRUITINGCleveland, Ohio, 44106, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Michigan Health West
RECRUITINGWyoming, Michigan, 49519, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.